The dopamine transporter is elevated in adults with attention deficit hyperactivity disorder (ADHD) compared with healthy controls [Lancet 354 (1999) 2132]. The findings have been confirmed by others in a different population using a different probe for the dopamine transporter. Notwithstanding the need to confirm these findings in a multi-center trial, several hypotheses are presented to account for these observations. A premise that elevated transporter levels result from medication is not supported by current data. Other possibilities, including hypertrophy of dopamine neuronal terminals in the striatum, dysfunctional regulation of dopamine or dopamine receptors, or anomalies in the dopamine transporter gene are presented as hypotheses. The feasibility of exploring these mechanisms in animal models or in human subjects is explored.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0166-4328(01)00439-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Genetic and Receptor-Based Dopaminergic Strategies for Antidepressant Drug Development.
Curr Gene Ther
January 2025
Department of Pharmacology, Delhi Pharmaceutical Sciences & Research University, Delhi, 110017, India.
The dopamine (DA) system is central to mood regulation, motivation, and reward processing, making it a critical focus for understanding Major Depressive Disorder (MDD). While the dopaminergic system's role in MDD pathophysiology has been acknowledged, gaps remain in linking specific receptor subtypes and genetic factors to depression-like phenotypes. This study explores the interplay between dopamine receptor subtypes (D1-D5) and associated genetic variations, particularly focusing on receptor heterodimers and polymorphisms influencing dopamine biosynthesis, signalling, and metabolism.
View Article and Find Full Text PDFDeficiency of orexin receptor type 1 in dopaminergic neurons increases novelty-induced locomotion and exploration.
Elife
January 2025
Max Planck Institute for Metabolism Research, Department of Neuronal Control of Metabolism, Cologne, Germany.
Orexin signaling in the ventral tegmental area and substantia nigra promotes locomotion and reward processing, but it is not clear whether dopaminergic neurons directly mediate these effects. We show that dopaminergic neurons in these areas mainly express orexin receptor subtype 1 (Ox1R). In contrast, only a minor population in the medial ventral tegmental area express orexin receptor subtype 2 (Ox2R).
View Article and Find Full Text PDFHinokinin Decreases Methamphetamine-Induced Hyperlocomotion via the Regulatory Effects on Dopamine Levels.
ACS Chem Neurosci
January 2025
College of Pharmacy, Chungbuk National University, 194-31 Osongsaengmyeong 1-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 28160, Republic of Korea.
The global abuse of stimulant methamphetamine (METH) imposes a significant social burden. Despite this, effective therapeutic interventions for mitigating the harmful effects associated with METH-induced central nervous system (CNS) stimulation remain elusive. (hinoki), containing hinokinin as its active constituent, has been identified to exhibit CNS depressant properties.
View Article and Find Full Text PDFChallenges in the management of visual and tactile hallucinations in elderly people.
World J Psychiatry
January 2025
Division of Geriatric Psychiatry, Department of Psychiatry, Changhua Christian Hospital, Changhua 500, Taiwan.
This letter provides a concise review of the pertinent literature on visual and tactile hallucinations in elderly patients. The discussion addresses differential diagnoses and potential underlying mechanisms, as well as the psychopathology associated with tactile hallucinations, and emphasizes the necessity for investigation into the possibility of coexisting delusional infestation (parasitosis). These symptoms frequently manifest in patients with primary psychotic disorders, organic mental disorders, and substance use disorders.
View Article and Find Full Text PDFCross-modality PET image synthesis for Parkinson's Disease diagnosis: a leap from [F]FDG to [C]CFT.
Eur J Nucl Med Mol Imaging
January 2025
Department of Nuclear Medicine/PET center, Huashan Hospital, Fudan University, Shanghai, 200235, China.
Purpose: Dopamine transporter [C]CFT PET is highly effective for diagnosing Parkinson's Disease (PD), whereas it is not widely available in most hospitals. To develop a deep learning framework to synthesize [C]CFT PET images from real [F]FDG PET images and leverage their cross-modal correlation to distinguish PD from normal control (NC).
Methods: We developed a deep learning framework to synthesize [C]CFT PET images from real [F]FDG PET images, and leveraged their cross-modal correlation to distinguish PD from NC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!